Relaxing patent rights in a pandemic is a win for innovators and the public
The long read: Womble Bond Dickinson’s Ben Bourke takes a deep dive into how life science companies have handled their IP portfolios over the covid-19 pandemic – in particular Moderna Therapeutics’ pledge not to enforce patents relating to its vaccine – and examines how such adjustments can prepare the ground for future inventions
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10